Structure-activity relationships of a peptidic antagonist of Id1 studied by biosensor method, circular dichroism spectroscopy, and bioassay

Journal of Peptide Science

Volumn 17, Issue 10, 2011, Pages 667-674

  Yang, Shih Ying ^a   Chen, Yeh ^b   Yang, Chia Xin ^c   Yang, De Len ^a   Kuo, Sheng Chu ^c   Huang, Li Jiau ^c   Lung, Feng Di T ^a  

^a TUNGHAI UNIVERSITY   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anticancer agents; CD; Id1 protein; MyoD protein; SAR; Surface plasmon resonance

Indexed keywords

PEPTIDE 3C; PEPTIDE 3C CTD4; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BIOASSAY; BIOSENSOR; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCULAR DICHROISM; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053219718     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1386     Document Type: Article

References (34)

1. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61(1): 49-59.
2. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001; 20(58): 8326-8333.
3. Mori S, Nishikawa SI, Yokota Y. Lactation defect in mice lacking the helix-loop-helix inhibitor Id2. Embo J. 2000; 19(21): 5772-5781.
4. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999; 401(6754): 670-677.
5. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994; 8(11): 1270-1284.
6. Hara E, Yamaguchi T, Nojima H, Ide T, Campisi J, Okayama H, Oda K. Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J. Biol. Chem. 1994; 269(3): 2139-2145.
7. Barone MV, Pepperkok R, Peverali FA, Philipson L. Id proteins control growth induction in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1994; 91(11): 4985-4988.
8. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003; 13(8): 410-418.
9. Zebedee Z, Hara E. Id proteins in cell cycle control and cellular senescence. Oncogene 2001; 20(58): 8317-8325.
10. Kee BL. E and ID proteins branch out. Nat. Rev. Immunol. 2009; 9(3): 175-184.
11. Ciarapica R, Annibali D, Raimondi L, Savino M, Nasi S, Rota R. Targeting Id protein interactions by an engineered HLH domain induces human neuroblastoma cell differentiation. Oncogene 2009; 28(17): 1881-1891.
12. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003; 3(6): 525-530.
13. Coppe JP, Smith AP, Desprez PY. Id proteins in epithelial cells. Exp. Cell Res. 2003; 285(1): 131-145.
14. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell. Sci. 2000; 113(Pt 22): 3897-3905.
15. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc. Natl. Acad. Sci. U.S.A. 1999; 96(17): 9637-9641.
16. Christy BA, Sanders LK, Lau LF, Copeland NG, Jenkins NA, Nathans D. An Id-related helix-loop-helix protein encoded by a growth factor-inducible gene. Proc. Natl. Acad. Sci. U.S.A. 1991; 88(5): 1815-1819.
17. Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res. Treat. 2010; 124(3): 623-633.
18. Lee JY, Kang MB, Jang SH, Qian T, Kim HJ, Kim CH, Kim Y, Kong G. Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. Oncogene 2009; 28(6): 824-831.
19. Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, Cheung AL. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 2007; 28(11): 2313-2320.
20. Lopez-Carballo G, Moreno L, Masia S, Perez P, Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 2002; 277(28): 25297-25304.
21. Su Y, Zheng L, Wang Q, Bao J, Cai Z, Liu A. The PI3K/Akt pathway upregulates Id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer 2010; 10: 459.
22. Pellegrino S, Ferri N, Colombo N, Cremona E, Corsini A, Fanelli R, Gelmi ML, Cabrele C. Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. Bioorg. Med. Chem. Lett. 2009; 19(22): 6298-6302.
23. Zhao ZR, Zhang ZY, Zhang H, Jiang L, Wang MW, Sun XF. Overexpression of Id-1 protein is a marker in colorectal cancer progression. Oncol. Rep. 2008; 19(2): 419-424.
24. Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK, Wang Q, Wang X, Wong YC. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005; 26(10): 1668-1676.
25. Lee KT, Lee YW, Lee JK, Choi SH, Rhee JC, Paik SS, Kong G. Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers. Br. J. Cancer 2004; 90(6): 1198-1203.
26. Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int. J. Cancer 2003; 104(6): 677-682.
27. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res. 2001; 61(15): 5703-5706.
28. Chen CH, Kuo SC, Huang LJ, Hsu MH, Lung FD. Affinity of synthetic peptide fragments of MyoD for Id1 protein and their biological effects in several cancer cells. J. Pept. Sci. 2010; 16(5): 231-241.
29. Lung FD, Tsai JY, Wei SY, Cheng JW, Chen C, Li P, Roller PP. Novel peptide inhibitors for Grb2 SH2 domain and their detection by surface plasmon resonance. J. Pept. Res. 2002; 60(3): 143-149.
30. Chang CD, Meienhofer J. Solid-phase peptide synthesis using mild base cleavage of N alpha-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int. J. Pept. Protein Res. 1978; 11(3): 246-249.
31. Merrifield RB. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 1969; 32: 221-296.
32. Lung FD, Tsai JY. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents. Biopolymers 2003; 71(2): 132-140.
33. Lung FD, Chen HY, Lin HT. Monitoring bone loss using ELISA and surface plasmon resonance (SPR) technology. Protein Pept. Lett. 2003; 10(3): 313-319.
34. Perez-Iratxeta C, Andrade-Navarro MA. K2D2: estimation of protein secondary structure from circular dichroism spectra. BMC Struct. Biol. 2008; 8: 25.